IRAK-M removal counteracts dendritic cell vaccine deficits in migration and longevity

Journal of Immunology

Volumn 185, Issue 7, 2010, Pages 4223-4232

  Turnis, Meghan E ^a,b   Song, Xiao Tong ^a,b   Bear, Adham ^a   Foster, Aaron E ^a,b   Gottschalk, Stephen ^a,b   Brenner, Malcolm K ^a,b   Chen, Si Yi ^b,c   Rooney, Cliona M ^a,b  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; LIPOPOLYSACCHARIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; TOLL LIKE RECEPTOR 1; CANCER VACCINE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE; IRAK3 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CULTURE; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; IN VITRO STUDY; IN VIVO STUDY; LONGEVITY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TH1 CELL; ANIMAL; ANTIGEN PRESENTATION; BAGG ALBINO MOUSE; C57BL MOUSE; CELL SEPARATION; CELL SURVIVAL; CYTOLOGY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; IMMUNOLOGY; METABOLISM; NEUTROPHIL CHEMOTAXIS; WESTERN BLOTTING;

ANIMALS; ANTIGEN PRESENTATION; BLOTTING, WESTERN; CANCER VACCINES; CELL PROLIFERATION; CELL SEPARATION; CELL SURVIVAL; CHEMOTAXIS, LEUKOCYTE; DENDRITIC CELLS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL;

EID: 77958126868     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0903507     Document Type: Article

References (51)

1. Steinman, R. M. 2003. Some interfaces of dendritic cell biology. APMIS 111:675-697.
2. Trombetta, E. S., and I. Mellman. 2005. Cell biology of antigen processing in vitro and in vivo. Annu. Rev. Immunol. 23:975-1028.
3. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245-252.
4. Grover, A., G. J. Kim, G. Lizée, M. Tschoi, G. Wang, J. R. Wunderlich, S. A. Rosenberg, S. T. Hwang, and P. Hwu. 2006. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes. Clin. Cancer Res. 12:5801-5808.
5. Lapteva, N., M. R. Seethammagari, B. A. Hanks, J. Jiang, J. M. Levitt, K. M. Slawin, and D. M. Spencer. 2007. Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Cancer Res. 67:10528-10537.
6. Maier, T., A. Tun-Kyi, A. Tassis, K. P. Jungius, G. Burg, R. Dummer, and F. O. Nestle. 2003. Vaccination of patients with cutaneous T-cell lymphoma using intranodal injection of autologous tumor-lysate-pulsed dendritic cells. Blood 102:2338-2344.
7. Nestle, F. O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadendorf. 1998. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
8. Timmerman, J. M., D. K. Czerwinski, T. A. Davis, F. J. Hsu, C. Benike, Z. M. Hao, B. Taidi, R. Rajapaksa, C. B. Caspar, C. Y. Okada, et al. 2002. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99:1517-1526.
9. Wierecky, J., M. R. Müller, S. Wirths, E. Halder-Oehler, D. Dörfel, S. M. Schmidt, M. Häntschel, W. Brugger, S. Schröder, M. S. Horger, et al. 2006. Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients. Cancer Res. 66:5910-5918.
10. Schuler, G., B. Schuler-Thurner, and R. M. Steinman. 2003. The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. 15:138-147.
11. Osada, T., T. M. Clay, C. Y. Woo, M. A. Morse, and H. K. Lyerly. 2006. Dendritic cell-based immunotherapy. Int. Rev. Immunol. 25:377-413.
12. Vieweg, J., and A. Jackson. 2005. Modulation of antitumor responses by dendritic cells. Springer Semin. Immunopathol. 26:329-341.
13. Allan, R. S., J. Waithman, S. Bedoui, C. M. Jones, J. A. Villadangos, Y. Zhan, A. M. Lew, K. Shortman, W. R. Heath, and F. R. Carbone. 2006. Migratory dendritic cells transfer antigen to a lymph node-resident dendritic cell population for efficient CTL priming. Immunity 25:153-162.
14. Allenspach, E. J., M. P. Lemos, P. M. Porrett, L. A. Turka, and T. M. Laufer. 2008. Migratory and lymphoid-resident dendritic cells cooperate to efficiently prime naive CD4 T cells. Immunity 29:795-806.
15. De Vries, I. J., D. J. Krooshoop, N. M. Scharenborg, W. J. Lesterhuis, J. H. Diepstra, G. N. Van Muijen, S. P. Strijk, T. J. Ruers, O. C. Boerman, W. J. Oyen, et al. 2003. Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. Cancer Res. 63:12-17.
16. Förster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Müller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23-33.
17. Verdijk, P., E. H. Aarntzen, W. J. Lesterhuis, A. C. Boullart, E. Kok, M. M. van Rossum, S. Strijk, F. Eijckeler, J. J. Bonenkamp, J. F. Jacobs, et al. 2009. Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potentialinmelanoma patients. Clin. Cancer Res. 15:2531-2540.
18. Reichardt, V. L., C. Milazzo, W. Brugger, H. Einsele, L. Kanz, and P. Brossart. 2003. Idiotype vaccination of multiple myeloma patients using monocytederived dendritic cells. Haematologica 88:1139-1149.
19. Evel-Kabler, K., X. T. Song, M. Aldrich, X. F. Huang, and S. Y. Chen. 2006. SOCS1 restricts dendritic cells' ability to break self tolerance and induce antitumor immunity by regulating IL-12 production and signaling. J. Clin. Invest. 116:90-100.
20. Shen, L., K. Evel-Kabler, R. Strube, and S. Y. Chen. 2004. Silencing of SOCS1 enhances antigen presentation by dendritic cells and antigen-specific anti-tumor immunity. Nat. Biotechnol. 22:1546-1553.
21. Song, X. T., K. Evel-Kabler, L. Shen, L. Rollins, X. F. Huang, and S. Y. Chen. 2008. A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat. Med. 14:258-265.
22. Kobayashi, K., L. D. Hernandez, J. E. Galán, C. A. Janeway, Jr., R. Medzhitov, and R. A. Flavell. 2002. IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110:191-202.
23. Deng, J. C., G. Cheng, M. W. Newstead, X. Zeng, K. Kobayashi, R. A. Flavell, and T. J. Standiford. 2006. Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J. Clin. Invest. 116:2532-2542.
24. Tazi, K. A., J. J. Quioc, V. Saada, A. Bezeaud, D. Lebrec, and R. Moreau. 2006. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J. Hepatol. 45:280-289.
25. Wiersinga, W. J., C. van't Veer, P. S. van den Pangaart, A. M. Dondorp, N. P. Day, S. J. Peacock, and T. van der Poll. 2009. Immunosuppression associated with interleukin-1R-associated-kinase-M upregulation predicts mortality in Gram-negative sepsis (melioidosis). Crit. Care Med. 37:569-576.
26. Hou, W. S., and L. Van Parijs. 2004. A Bcl-2-dependent molecular timer regulates the lifespan and immunogenicity of dendritic cells. Nat. Immunol. 5:583-589.
27. Jung, I. D., J. S. Lee, Y. J. Kim, Y. I. Jeong, C. M. Lee, M. G. Lee, S. C. Ahn, and Y. M. Park. 2007. Sphingosine kinase inhibitor suppresses dendritic cell migration by regulating chemokine receptor expression and impairing p38 mitogen-activated protein kinase. Immunology 121:533-544.
28. Ouaaz, F., J. Arron, Y. Zheng, Y. Choi, and A. A. Beg. 2002. Dendritic cell development and survival require distinct NF-kappaB subunits. Immunity 16:257-270.
29. Randolph, G. J., G. Sanchez-Schmitz, and V. Angeli. 2005. Factors and signals that govern the migration of dendritic cells via lymphatics: recent advances. Springer Semin. Immunopathol. 26:273-287.
30. Agrawal, S., A. Agrawal, B. Doughty, A. Gerwitz, J. Blenis, T. Van Dyke, and B. Pulendran. 2003. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171:4984-4989.
31. Daly, C., and B. J. Rollins. 2003. Monocyte chemoattractant protein-1 (CCL2) in inflammatory disease and adaptive immunity: therapeutic opportunities and controversies. Microcirculation 10:247-257.
32. Marsland, B. J., P. Bättig, M. Bauer, C. Ruedl, U. Lässing, R. R. Beerli, K. Dietmeier, L. Ivanova, T. Pfister, L. Vogt, et al. 2005. CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 22:493-505.
33. Gunn, M. D. 2003. Chemokine mediated control of dendritic cell migration and function. Semin. Immunol. 15:271-276.
34. Butterfield, L. H., B. Comin-Anduix, L. Vujanovic, Y. Lee, V. B. Dissette, J. Q. Yang, H. T. Vu, E. Seja, D. K. Oseguera, D. M. Potter, et al. 2008. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J. Immunother. 31:294-309.
35. Li, H., E. Cuartas, W. Cui, Y. Choi, T. D. Crawford, H. Z. Ke, K. S. Kobayashi, R. A. Flavell, and A. Vignery. 2005. IL-1 receptor-associated kinase M is a central regulator of osteoclast differentiation and activation. J. Exp. Med. 201:1169-1177.
36. Wesche, H., X. Gao, X. Li, C. J. Kirschning, G. R. Stark, and Z. Cao. 1999. IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J. Biol. Chem. 274:19403-19410.
37. Martin-Fontecha, A., S. Sebastiani, U. E. Höpken, M. Uguccioni, M. Lipp, A. Lanzavecchia, and F. Sallusto. 2003. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte traffic and priming. J. Exp. Med. 198:615-621.
38. Giermasz, A. S., J. A. Urban, Y. Nakamura, P. Watchmaker, R. L. Cumberland, W. Gooding, and P. Kalinski. 2009. Type-1 polarized dendritic cells primed for high IL-12 production show enhanced activity as cancer vaccines. Cancer Immunol. Immunother. 58:1329-1336.
39. Trinchieri, G. 2003. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3:133-146.
40. Chen, M., L. Huang, Z. Shabier, and J. Wang. 2007. Regulation of the lifespan in dendritic cell subsets. Mol. Immunol. 44:2558-2565.
41. Kaka, A. S., A. E. Foster, H. L. Weiss, C. M. Rooney, and A. M. Leen. 2008. Using dendritic cell maturation and IL-12 producing capacity as markers of function: a cautionary tale. J. Immunother. 31:359-369.
42. Gautier, E. L., T. Huby, F. Saint-Charles, B. Ouzilleau, M. J. Chapman, and P. Lesnik. 2008. Enhanced dendritic cell survival attenuates lipopolysaccharideinduced immunosuppression and increases resistance to lethal endotoxic shock. J. Immunol. 180:6941-6946.
43. Elliott, B., R. A. Scolyer, S. Suciu, S. Lebecque, D. Rimoldi, O. Gugerli, E. Musat, R. N. Sharma, D. Lienard, U. Keilholz, et al; European Organization for Research and Treatment of Cancer Melanoma Group. 2007. Long-term protective effect of mature DC-LAMP+ dendritic cell accumulation in sentinel lymph nodes containing micrometastatic melanoma. Clin. Cancer Res. 13:3825-3830.
44. Park, D., N. Lapteva, M. Seethammagari, K. M. Slawin, and D. M. Spencer. 2006. An essential role for Akt1 in dendritic cell function and tumor immunotherapy. Nat. Biotechnol. 24:1581-1590.
45. Heckelsmiller, K., S. Beck, K. Rall, B. Sipos, A. Schlamp, E. Tuma, S. Rothenfusser, S. Endres, and G. Hartmann. 2002. Combined dendritic celland CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 32:3235-3245.
46. Broomfield, S. A., R. G. van der Most, A. C. Prosser, S. Mahendran, M. G. Tovey, M. J. Smyth, B. W. Robinson, and A. J. Currie. 2009. Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J. Immunol. 182:5217-5224.
47. Tatsumi, T., J. Huang, W. E. Gooding, A. Gambotto, P. D. Robbins, N. L. Vujanovic, S. M. Alber, S. C. Watkins, H. Okada, and W. J. Storkus. 2003. Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. Cancer Res. 63:6378-6386.
48. Wiethe, C., K. Dittmar, T. Doan, W. Lindenmaier, and R. Tindle. 2003. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. J. Immunol. 171:4121-4130.
49. Nogai, A., V. Siffrin, K. Bonhagen, C. F. Pfueller, T. Hohnstein, R. Volkmer-Engert, W. Brück, C. Stadelmann, and T. Kamradt. 2005. Lipopolysaccharide injection induces relapses of experimental autoimmune encephalomyelitis in nontransgenic mice via bystander activation of autoreactive CD4+ cells. J. Immunol. 175:959-966.
50. Marine, J. C., D. J. Topham, C. McKay, D. Wang, E. Parganas, D. Stravopodis, A. Yoshimura, and J. N. Ihle. 1999. SOCS1 deficiency causes a lymphocytedependent perinatal lethality. Cell 98:609-616.
51. Lee, E. G., D. L. Boone, S. Chai, S. L. Libby, M. Chien, J. P. Lodolce, and A. Ma. 2000. Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science 289:2350-2354.